RDHL Redhill Biopharma Ltd.
Listings ·
Nasdaq gave Redhill Biopharma until April 5, 2027 to regain the $1.00 minimum bid price, in a letter dated October 6, 2026. The American Depositary Shares keep trading on The Nasdaq Capital Market as RDHL, but the company's cash was last reported at $2.9 million in mid-2025.
Redhill Biopharma agreed on June 18, 2026 to sell 8,571,429 ADSs at $0.70 each with two series of warrants. The upfront money is about $6 million, and the warrants add about $13.4 million only if they are exercised for cash, which the company says is not assured.
| Line | FY2024 | FY2023 |
|---|---|---|
| Revenue | $8.0 million | $6.5 million |
| Research and development | $1.6 million | $3.5 million |
| Net income (loss) | -$8.3 million | $23.9 million |
| Cash from operations | -$9.4 million | -$35.8 million |
| Cash and equivalents | $4.6 million | $5.6 million |
Our latest story on this, dated Jun 18, 2026: "Redhill Biopharma signs $6 million private placement, up to $19.4 million with warrants". The story links the filing or release it is based on. Read the story.
Redhill Biopharma Ltd. trades under the ticker RDHL on NASDAQ.
Redhill Biopharma Ltd. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Redhill Biopharma Ltd. is 1553846. Its filings are on SEC EDGAR.
50,923,261,000 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-27.
Our directory records Redhill Biopharma Ltd. under Israel.
Our directory classifies Redhill Biopharma Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Redhill Biopharma Ltd. is US7574683014.
aibio.space lists Redhill Biopharma Ltd. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as L3.
$8.0 million for the fiscal year ended Dec 31, 2024, as reported to the SEC.
Redhill Biopharma Ltd. reported a net loss of $8.3 million for the fiscal year ended Dec 31, 2024, and used $9.4 million of cash in operations, per its annual report to the SEC.
$1.6 million in the fiscal year ended Dec 31, 2024, per its annual report.
$2.9 million in cash at Jun 30, 2025, per its 6-K.
Our latest story on Redhill Biopharma, dated Oct 7, 2026: "Redhill Biopharma gets 180 more days on Nasdaq bid price, to April 5, 2027". Nasdaq gave Redhill Biopharma until April 5, 2027 to regain the $1.00 minimum bid price, in a letter dated October 6, 2026. The American Depositary Shares keep trading on The Nasdaq Capital Market as RDHL, but the company's cash was last reported at $2.9 million in mid-2025. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio